{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:55:18Z","timestamp":1781654118794,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cllc.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:25:14Z","timestamp":1777674314000},"page":"42-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Immune Checkpoint Inhibitor-Combined Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer With Brain Metastases"],"prefix":"10.1016","volume":"27","author":[{"given":"Amira","family":"Aliouat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Chareire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teo","family":"Bodergat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Moncharmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lasvergnas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebva","family":"Zysman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Pinsolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Guibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Tekhneriadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvire","family":"Pons-Tostivint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Toffart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.04.008_bib0001","doi-asserted-by":"crossref","first-page":"21\u20119","DOI":"10.1016\/j.jtho.2020.09.012","article-title":"Lung cancer in France","volume":"16","author":"Pujol","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"14","key":"10.1016\/j.cllc.2026.04.008_bib0002","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2026.04.008_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1001\/jamaoncol.2022.5049","volume":"8","author":"Palmer","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2026.04.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.wneu.2020.10.124","article-title":"Stereotactic radiosurgery results for patients with 5-10 versus 11-20 brain metastases: a retrospective cohort study combining 2 databases totaling 2319 patients","volume":"146","author":"Yamamoto","year":"2021","journal-title":"World Neurosurg"},{"issue":"21","key":"10.1016\/j.cllc.2026.04.008_bib0005","doi-asserted-by":"crossref","first-page":"2018\u201128","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cllc.2026.04.008_bib0006","doi-asserted-by":"crossref","first-page":"1244\u201154","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with non\u2013Small cell lung cancer and brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2026.04.008_bib0007","doi-asserted-by":"crossref","first-page":"916\u201125","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"28","key":"10.1016\/j.cllc.2026.04.008_bib0008","doi-asserted-by":"crossref","first-page":"4478\u201185","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of Atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non\u2013Small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.cllc.2026.04.008_bib0009","doi-asserted-by":"crossref","first-page":"91\u20119","DOI":"10.1007\/s00262-022-03232-2","article-title":"First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score \u2265 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)","volume":"72","author":"Descourt","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cllc.2026.04.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107321","article-title":"Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis","volume":"184","author":"Nigen","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2026.04.008_bib0019","doi-asserted-by":"crossref","first-page":"95\u2011107","DOI":"10.1016\/j.cllc.2021.06.009","article-title":"Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis","volume":"23","author":"Yang","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"30","key":"10.1016\/j.cllc.2026.04.008_bib0011","first-page":"3317\u201127","article-title":"Intracranial response of patients with non-small cell lung cancer and untreated brain metastases treated with PD-1\/PD-L1 inhibitors","volume":"39","author":"Mansfield","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.cllc.2026.04.008_bib0013","doi-asserted-by":"crossref","first-page":"2078\u201192","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013Small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2026.04.008_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.15510","article-title":"Immune checkpoint inhibitors +\/\u2212 chemotherapy for patients with NSCLC and brain metastases: a systematic review and network meta-analysis","volume":"16","author":"Brown","year":"2025","journal-title":"Thorac Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2026.04.008_bib0015","doi-asserted-by":"crossref","first-page":"907\u201116","DOI":"10.1097\/WCO.0000000000000756","article-title":"Complications associated with immunotherapy for brain metastases","volume":"32","author":"Tran","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.cllc.2026.04.008_bib0016","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"13","author":"Dubey","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.cllc.2026.04.008_bib0017","first-page":"125\u201137","article-title":"Patterns and outcomes of neurological adverse events associated with immune checkpoint inhibitors","volume":"15","author":"Kyi","year":"2023","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.cllc.2026.04.008_bib0018","first-page":"7036\u201111","article-title":"A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer","volume":"15","author":"Lu","year":"2025","journal-title":"Scient Rep"},{"issue":"4","key":"10.1016\/j.cllc.2026.04.008_bib0020","doi-asserted-by":"crossref","first-page":"689","DOI":"10.21037\/tlcr-22-515","article-title":"Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Chen","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"10.1016\/j.cllc.2026.04.008_bib0021","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.21037\/tlcr-23-347","article-title":"Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer","volume":"12","author":"Christopoulos","year":"2023","journal-title":"Transl Lung Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:23:14Z","timestamp":1781652194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525730426000604"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Immune Checkpoint Inhibitor-Combined Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer With Brain Metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}